Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
ASSETS
Cash and cash equivalents	$ 11,754	$ 10,299
Marketable securities	21,901	32,754
Prepaid and other current assets	1,163	1,053
Total current assets	34,818	44,106
Property and equipment, net	130	165
Other assets	1,402	309
Total assets	36,350	44,580
Liabilities
Accounts payable	559	762
Accrued liabilities	5,153	4,857
Total current liabilities	5,712	5,619
Other long-term liabilities	1,016	1,507
Total liabilities	6,728	7,126
Commitments and Contingencies
Stockholders' Equity
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at June 30, 2019 and December 31, 2018, respectively	0	0
Common stock, $0.001 par value, authorized 500,000,000 shares; issued and outstanding, 10,412,750 and 9,865,735 shares at June 30, 2019 and December 31, 2018, respectively	10	10
Additional paid-in capital	438,133	436,433
Treasury stock, at cost; 11,080 shares at June 30, 2019 and December 31, 2018	(708)	(708)
Accumulated deficit	(407,546)	(397,977)
Accumulated other comprehensive loss	0	(32)
Total Caladrius Biosciences, Inc. stockholders' equity	29,889	37,726
Noncontrolling interests	(267)	(272)
Total stockholders' equity	29,622	37,454
Liabilities and Equity, Total	$ 36,350	$ 44,580